CervoMed to Participate in Upcoming Investor Conferences

Rhea-AI Summary

CervoMed (NASDAQ: CRVO) announced management will participate in investor conferences in March 2026, including 1x1 investor meetings at the Leerink Global Healthcare Conference on March 11, 2026, and a fireside chat plus meetings at the 38th Annual ROTH Conference on March 23, 2026.

The ROTH fireside chat is scheduled for 12:00–12:30 PM PT on March 23, 2026; the webcast will be accessible in the Investor section of CervoMed's website.

News Market Reaction – CRVO

-0.25%

1 alert

-0.25% News Effect

-$87K Valuation Impact

$35M Market Cap

0.2x Rel. Volume

On the day this news was published, CRVO declined 0.25%, reflecting a mild negative market reaction. This price movement removed approximately $87K from the company's valuation, bringing the market cap to $35M at that time.

Data tracked by StockTitan Argus on the day of publication.

BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that Company management will participate in the following investor conferences during the month of March:

Leerink Global Healthcare Conference
Format: 1x1 Investor Meetings
Date: Wednesday, March 11, 2026

38^th Annual ROTH Conference
Format: Fireside Chat & 1x1 Investor Meetings
Presentation Date: Monday, March 23, 2026
Presentation Time: 12:00 – 12:30 PM PT

The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https://ir.cervomed.com/news-events/events-and-presentations

About CervoMed
CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in DLB patients who have a low likelihood of AD co-pathology, and the Company plans to initiate a global, pivotal Phase 3 trial in the same patient population in the second half of 2026, subject to available funding.

Contacts:

Media:
Lisa Guiterman
Biongage Communications
lisa.guiterman@gmail.com
202-330-3431

Investor Relations:
Argot Partners
cervomed@argotpartners.com
212-600-1902 

FAQ

When will CervoMed (CRVO) present at the ROTH Conference in March 2026?

CervoMed will present on March 23, 2026 at 12:00–12:30 PM PT with a fireside chat. According to CervoMed, the fireside chat webcast will be available in the Investor section of the company's website for remote viewers.

What investor events is CervoMed (CRVO) attending in March 2026?

CervoMed is attending 1x1 investor meetings at Leerink on March 11 and the 38th Annual ROTH Conference on March 23. According to CervoMed, management will hold both one-on-one meetings and a ROTH fireside chat during March.

How can investors access the CervoMed (CRVO) ROTH fireside chat webcast?

The ROTH fireside chat webcast will be accessible via the Investor section of CervoMed's website. According to CervoMed, investors should visit the company's news and events page to view the live webcast and archived presentation.

Will CervoMed (CRVO) hold one-on-one investor meetings at the March 2026 conferences?

Yes. CervoMed management will conduct 1x1 investor meetings at both the Leerink Global Healthcare Conference and ROTH Conference in March 2026. According to CervoMed, these meetings complement the scheduled ROTH fireside chat on March 23.

What is the scheduled date for CervoMed's (CRVO) Leerink Global Healthcare Conference meetings?

CervoMed's Leerink one-on-one investor meetings are scheduled for Wednesday, March 11, 2026. According to CervoMed, management will participate in 1x1 investor meetings at the Leerink Global Healthcare Conference that day.